{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:10:45Z","timestamp":1786119045614,"version":"build-2736575974"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1097\/bor.0b013e32831ca5c5","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T03:20:46Z","timestamp":1228965646000},"page":"55-61","source":"Crossref","is-referenced-by-count":5,"title":["Rheumatic manifestations of renal disease"],"prefix":"10.1097","volume":"21","author":[{"given":"Thomas","family":"Bardin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Richette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210128","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5002769","article-title":"K\/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients","volume":"73","author":"Barreto","year":"2008","journal-title":"Kidney Int"},{"key":"R2-11-20210128","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1681\/ASN.2006101089","article-title":"Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients","volume":"19","author":"Ferreira","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R4-11-20210128","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00467-007-0508-0","article-title":"Parathyroid hormone assay: problems and opportunities","volume":"22","author":"Martin","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"R5-11-20210128","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0085-2538(15)47156-X","article-title":"A novel mechanism for skeletal resistance in uremia","volume":"58","author":"Slatopolsky","year":"2000","journal-title":"Kidney Int"},{"key":"R6-11-20210128","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.ki.5001606","article-title":"Inter-method variability in PTH measurement: implication for the care of CKD patients","volume":"70","author":"Souberbielle","year":"2006","journal-title":"Kidney Int"},{"key":"R7-11-20210128","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00002281-200301000-00009","article-title":"Musculoskeletal manifestations of chronic renal failure","volume":"15","author":"Bardin","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"R8-11-20210128","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1161\/hy1001.096358","article-title":"Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease","volume":"38","author":"Blacher","year":"2001","journal-title":"Hypertension"},{"key":"R10-11-20210128","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1681\/ASN.2007070760","article-title":"The mechanism of phosphorus as a cardiovascular risk factor in CKD","volume":"19","author":"Mathew","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R11-11-20210128","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/sj.ki.5002646","article-title":"Metabolic acidosis inhibits soft tissue calcification in uremic rats","volume":"73","author":"Mendoza","year":"2008","journal-title":"Kidney Int"},{"key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ki.2008.130","article-title":"Hyperphosphatemia of chronic kidney disease","volume":"74","author":"Hruska","year":"2008","journal-title":"Kidney Int"},{"key":"R13-11-20210128","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.atherosclerosis.2007.11.031","article-title":"BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells","volume":"199","author":"Li","year":"2008","journal-title":"Atherosclerosis"},{"key":"R14-11-20210128","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1681\/ASN.2007050622","article-title":"Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD","volume":"19","author":"London","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R15-11-20210128","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.070305","article-title":"Differential effects of vitamin D analogs on vascular calcification","volume":"22","author":"Cardus","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R16-11-20210128","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1681\/ASN.2007080902","article-title":"Vitamin D receptor activators can protect against vascular calcification","volume":"19","author":"Mathew","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R17-11-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"R18-11-20210128","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/ki.2008.4","article-title":"Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease","volume":"73","author":"Gutierrez","year":"2008","journal-title":"Kidney Int"},{"key":"R19-11-20210128","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4158\/EP.14.1.18","article-title":"Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease","volume":"14","author":"Andress","year":"2008","journal-title":"Endocr Pract"},{"key":"R20-11-20210128","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R21-11-20210128","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1440-1797.2007.00860.x","article-title":"Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4","volume":"13","author":"Stavroulopoulos","year":"2008","journal-title":"Nephrology (Carlton)"},{"key":"R22-11-20210128","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1681\/ASN.2007060673","article-title":"Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD","volume":"19","author":"Isakova","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R23-11-20210128","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"R24-11-20210128","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/ki.2008.64","article-title":"Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease","volume":"73","author":"Kovesdy","year":"2008","journal-title":"Kidney Int"},{"key":"R25-11-20210128","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/sj.ki.5002716","article-title":"Nontraditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort","volume":"73","author":"Baber","year":"2008","journal-title":"Kidney Int"},{"key":"R26-11-20210128","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2007.110","article-title":"Association of activated vitamin D treatment and mortality in chronic kidney disease","volume":"168","author":"Kovesdy","year":"2008","journal-title":"Arch Intern Med"},{"key":"R27-11-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1744-9987.2007.00541.x","article-title":"Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis","volume":"12","author":"Shigematsu","year":"2008","journal-title":"Ther Apher Dial"},{"key":"R28-11-20210128","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"key":"R29-11-20210128","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/ndt\/gfh894","article-title":"Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density","volume":"20","author":"Asmus","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R30-11-20210128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"R31-11-20210128","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","article-title":"Meta-analysis: vitamin D compounds in chronic kidney disease","volume":"147","author":"Palmer","year":"2007","journal-title":"Ann Intern Med"},{"key":"R32-11-20210128","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","article-title":"Vitamin D levels and early mortality among incident hemodialysis patients","volume":"72","author":"Wolf","year":"2007","journal-title":"Kidney Int"},{"key":"R33-11-20210128","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.ki.5002544","article-title":"Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients: the need for randomized trials","volume":"72","author":"Al-Aly","year":"2007","journal-title":"Kidney Int"},{"key":"R34-11-20210128","doi-asserted-by":"crossref","first-page":"880","DOI":"10.7326\/0003-4819-147-12-200712180-00009","article-title":"Vitamin D in patients with chronic kidney disease: nothing new under the sun","volume":"147","author":"Tonelli","year":"2007","journal-title":"Ann Intern Med"},{"key":"R35-11-20210128","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"R36-11-20210128","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/ndt\/gfm177","article-title":"Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies","volume":"22","author":"Drueke","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R37-11-20210128","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1365-2362.2007.01874.x","article-title":"The role of calcimimetics in the treatment of hyperparathyroidism","volume":"37","author":"Wuthrich","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"R38-11-20210128","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5414\/CNP69269","article-title":"An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism","volume":"69","author":"Malluche","year":"2008","journal-title":"Clin Nephrol"},{"key":"R39-11-20210128","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/ndt\/gfn026","article-title":"Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism","volume":"23","author":"Block","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R40-11-20210128","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism","volume":"3","author":"Messa","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R41-11-20210128","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfm172","article-title":"Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism","volume":"22","author":"Jean","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R43-11-20210128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejrad.2008.01.016","article-title":"Clinical and histological findings in nephrogenic systemic fibrosis","volume":"66","author":"Cowper","year":"2008","journal-title":"Eur J Radiol"},{"key":"R44-11-20210128","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaad.2008.02.038","article-title":"Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement","volume":"58","author":"Kelly","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R45-11-20210128","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","article-title":"Gadolinium\u2013a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?","volume":"21","author":"Grobner","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R46-11-20210128","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1365-2133.2008.08506.x","article-title":"A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?","volume":"158","author":"Singh","year":"2008","journal-title":"Br J Dermatol"},{"key":"R47-11-20210128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2133.2007.08335.x","article-title":"Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis","volume":"158","author":"Abraham","year":"2008","journal-title":"Br J Dermatol"},{"key":"R48-11-20210128","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jaad.2008.04.010","article-title":"Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors","volume":"59","author":"Khurana","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R49-11-20210128","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2215\/CJN.00100108","article-title":"Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease","volume":"3","author":"Schroeder","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R50-11-20210128","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.2214\/AJR.07.2822","article-title":"Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue","volume":"190","author":"Wiginton","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"R51-11-20210128","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/MNH.0b013e3282f4b605","article-title":"Nephrogenic systemic fibrosis: epidemiology update","volume":"17","author":"Marckmann","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R52-11-20210128","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/art.22925","article-title":"Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure","volume":"56","author":"Todd","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R53-11-20210128","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1148\/radiol.2431062144","article-title":"Nephrogenic systemic fibrosis: risk factors and incidence estimation","volume":"243","author":"Sadowski","year":"2007","journal-title":"Radiology"},{"key":"R54-11-20210128","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1111\/j.1600-6143.2007.01941.x","article-title":"Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature","volume":"7","author":"Wahba","year":"2007","journal-title":"Am J Transplant"},{"key":"R55-11-20210128","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejrad.2008.01.025","article-title":"Extracellular gadolinium contrast agents: differences in stability","volume":"66","author":"Morcos","year":"2008","journal-title":"Eur J Radiol"},{"key":"R56-11-20210128","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/path.2311","article-title":"Gadodiamide contrast agent \u2018activates\u2019 fibroblasts: a possible cause of nephrogenic systemic fibrosis","volume":"214","author":"Edward","year":"2008","journal-title":"J Pathol"},{"key":"R57-11-20210128","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1007\/s00330-008-0977-y","article-title":"Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions","volume":"18","author":"Sieber","year":"2008","journal-title":"Eur Radiol"},{"key":"R59-11-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/RLI.0b013e31815a3407","article-title":"High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent","volume":"43","author":"Rydahl","year":"2008","journal-title":"Invest Radiol"},{"key":"R60-11-20210128","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/ki.2008.76","article-title":"Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis","volume":"73","author":"Swaminathan","year":"2008","journal-title":"Kidney Int"},{"key":"R61-11-20210128","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.forsciint.2007.06.026","article-title":"Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis","volume":"176","author":"Saussereau","year":"2008","journal-title":"Forensic Sci Int"},{"key":"R62-11-20210128","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2214\/AJR.07.2884","article-title":"Nephrogenic systemic fibrosis: possible association with a predisposing infection","volume":"190","author":"Golding","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"R63-11-20210128","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMc070248","article-title":"Nephrogenic systemic fibrosis, gadolinium, and iron mobilization","volume":"357","author":"Swaminathan","year":"2007","journal-title":"N Engl J Med"},{"key":"R64-11-20210128","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1053\/j.ajkd.2007.12.036","article-title":"Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study","volume":"51","author":"Kallen","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R65-11-20210128","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1093\/ndt\/gfm261","article-title":"Case-control study of gadodiamide-related nephrogenic systemic fibrosis","volume":"22","author":"Marckmann","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R66-11-20210128","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1056\/NEJMcpc0708697","article-title":"Case 6-2008: a 46-year-old woman with renal failure and stiffness of the joints and skin","volume":"358","author":"Kay","year":"2008","journal-title":"N Engl J Med"},{"key":"R67-11-20210128","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1053\/j.ajkd.2007.12.037","article-title":"Successful pregnancy in a hemodialysis patient and marked resolution of her nephrogenic systemic fibrosis","volume":"51","author":"Khurana","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R68-11-20210128","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1093\/ndt\/gfn217","article-title":"Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis","volume":"23","author":"Marckmann","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R69-11-20210128","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2215\/CJN.03250906","article-title":"Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure\u2013role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate","volume":"2","author":"Yerram","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R70-11-20210128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1525-139X.2007.00402.x","article-title":"Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney disease","volume":"21","author":"Perazella","year":"2008","journal-title":"Semin Dial"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e32831ca5c5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:26:23Z","timestamp":1786037183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-200901000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e32831ca5c5","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}